- Home
- OPRT vs KYTX Comparison
OPRT vs KYTX Comparison
Compare OPRT & KYTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPRT
- KYTX
- Stock Information
- Founded
- OPRT 2005
- KYTX 2018
- Country
- OPRT United States
- KYTX United States
- Employees
- OPRT N/A
- KYTX N/A
- Industry
- OPRT Finance: Consumer Services
- KYTX
- Sector
- OPRT Finance
- KYTX
- Exchange
- OPRT Nasdaq
- KYTX NYSE
- Market Cap
- OPRT 146.4M
- KYTX 130.8M
- IPO Year
- OPRT 2019
- KYTX 2024
- Fundamental
- Price
- OPRT $7.89
- KYTX $2.78
- Analyst Decision
- OPRT Buy
- KYTX Buy
- Analyst Count
- OPRT 4
- KYTX 5
- Target Price
- OPRT $5.17
- KYTX $23.20
- AVG Volume (30 Days)
- OPRT 810.8K
- KYTX 474.5K
- Earning Date
- OPRT 02-12-2025
- KYTX 03-04-2025
- Dividend Yield
- OPRT N/A
- KYTX N/A
- EPS Growth
- OPRT N/A
- KYTX N/A
- EPS
- OPRT N/A
- KYTX N/A
- Revenue
- OPRT $763,600,000.00
- KYTX N/A
- Revenue This Year
- OPRT N/A
- KYTX N/A
- Revenue Next Year
- OPRT $8.34
- KYTX N/A
- P/E Ratio
- OPRT N/A
- KYTX N/A
- Revenue Growth
- OPRT N/A
- KYTX N/A
- 52 Week Low
- OPRT $2.05
- KYTX $2.65
- 52 Week High
- OPRT $9.25
- KYTX $30.60
- Technical
- Relative Strength Index (RSI)
- OPRT 77.71
- KYTX 36.42
- Support Level
- OPRT $5.43
- KYTX $2.65
- Resistance Level
- OPRT $9.25
- KYTX $3.11
- Average True Range (ATR)
- OPRT 0.71
- KYTX 0.22
- MACD
- OPRT 0.27
- KYTX 0.01
- Stochastic Oscillator
- OPRT 72.59
- KYTX 17.88
About OPRT Oportun Financial Corporation
Oportun Financial Corp is engaged in providing financial services to people who either do not have a credit score or who may have a limited credit history. The company offers Personal Loans, Auto Loans, unsecured personal loans, and secured personal loans, and provides deposit accounts, debit card services, and other transaction services to its customers. Its product offerings include small-dollar, unsecured installment loans and other products and services.
About KYTX KYVERNA THERAPEUTICS INC
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.